Stocks and Investing
Stocks and Investing
Thu, December 1, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Steve Chesney Maintained (BIIB) at Hold with Increased Target to $295 on, Dec 1st, 2022
Steve Chesney of Atlantic Equities, Maintained "Biogen Inc." (BIIB) at Hold with Increased Target from $220 to $295 on, Dec 1st, 2022.
Steve has made no other calls on BIIB in the last 4 months.
There are 20 other peers that have a rating on BIIB. Out of the 20 peers that are also analyzing BIIB, 5 agree with Steve's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Carter Gould of "Barclays" Maintained at Hold with Increased Target to $313 on, Wednesday, November 30th, 2022
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $247 on, Wednesday, November 30th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Hold with Increased Target to $270 on, Friday, November 11th, 2022
- Chris Schott of "JP Morgan" Maintained at Hold with Increased Target to $275 on, Friday, September 30th, 2022
- Christopher Raymond of "Piper Sandler" Maintained at Hold with Increased Target to $280 on, Wednesday, September 28th, 2022
These are the ratings of the 15 analyists that currently disagree with Steve
- Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, November 30th, 2022
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $350 on, Tuesday, November 15th, 2022
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $315 on, Monday, November 14th, 2022
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $325 on, Tuesday, November 1st, 2022
- Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $370 on, Wednesday, October 26th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $310 on, Wednesday, October 26th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $325 on, Wednesday, October 26th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $325 on, Wednesday, October 26th, 2022
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $331 on, Wednesday, October 26th, 2022
- Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Held Target at $299 on, Thursday, October 13th, 2022
- Jasper Hellweg of "Argus Research" Upgraded from Hold to Strong Buy on, Friday, October 7th, 2022
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $309 on, Thursday, October 6th, 2022
- Brian Skorney of "Baird" Upgraded from Hold to Buy and Increased Target to $340 on, Wednesday, September 28th, 2022
- Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $360 on, Wednesday, September 28th, 2022
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $350 on, Wednesday, September 28th, 2022
Contributing Sources